J&J has also submitted rolling review submissions in other parts of the world and is seeking emergency use listing with the World Health Organization. Janssen’s Covid-19 has already received emergency use authorisations in the US and Canada.
“Now, as we await a decision on the use of our single-dose COVID-19 vaccine in the European Union, we remain confident that the J&J vaccine will prove a critical tool for fighting this pandemic.” J&J chief scientific officer and vice-chairman of the executive committee Paul Stoffels commented: “The EMA’s recommendation is a landmark moment for J&J and for the world. In the Phase III ENSEMBLE study, which was carried out in the US, South Africa, as well as countries across Latin America, Janssen’s Covid-19 vaccine was found to be 67% effective at preventing symptomatic Covid-19 and 85% effective at preventing severe disease.ĮMA executive director Emer Cooke said: “With this latest positive opinion, authorities across the European Union will have another option to combat the pandemic and protect the lives and health of their citizens.” The committee determined that the data for the vaccine was robust and met the criteria for efficacy, safety and quality. A dozen European countries today said they will resume vaccinations with the AstraZeneca vaccine against COVID-19 after the European Medicines Agency (EMA).
Ema approved vaccines trial#
The recommendation came after a thorough evaluation by the EMA’s Committee for Medicinal Products for Human Use of clinical trial data submitted by J&J in December. What are the potential growth opportunities?.How might the Chinese government react?.Spotlight on Shanghai: what is the situation there?.What is the effect of lockdowns on Chinese ports?.What is the effect of lockdowns on foodservice?.Which multinational companies have been affected?.Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers.
COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains.Ĭhina’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn.
0 kommentar(er)
